Zikán M, Pavlista D, Velenská Z, Cibula D
Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha.
Ceska Gynekol. 2009 Apr;74(2):102-5.
To characterize molecular pattern differences (LOH and expression) between DCIS and invasive breast cancer.
Original paper.
Oncogynecologic center, Clinic of Obstetrics and gynecology, First Faculty of Medicine, Charles University in Prague and General Teaching Hospital, Prague.
We analyzed LOH in 3 genes (BRCA1, BRCA2 and p53) and expression of 2 genes (VEGF and Bcl-2) in fresh frozen tissue samples of DCIS and invasive breast cancer. Each sample was evaluated by pathologist before sampling and analysis.
Molecular pattern analysis was performed in three types of tissue: healthy breast gland (65 samples), DCIS (25 samples) and invasive breast cancer (42 samples). LOH in BRCA1 was detected in 22.3% of invasive cancer samples and in 13.4% of DCIS; BRCA2 LOH in 32.1% of invasive cancer samples and in 14.1% of DCIS; p53 LOH in 35.6% of invasive cancer samples and in 33.2% of DCIS. VEGF was overexpressed in 15.3% of invasive cancer samples and in 8.3% of DCIS. Overexpression of Bcl-2 was detected in 13.2% of invasive breast cancer samples and in 7.1% of DCIS.
We confirmed that substantial part of DCIS has molecular pattern similar to invasive cancer. These molecular changes could serve as potential markers of DCIS progression to invasive cancer or they could identify subgroup of DCIS with latent invasion.
描述导管原位癌（DCIS）与浸润性乳腺癌之间的分子模式差异（杂合性缺失和表达情况）。
原创论文。
布拉格查理大学医学院第一附属医院妇产科肿瘤妇科中心及布拉格综合教学医院。
我们分析了DCIS和浸润性乳腺癌新鲜冷冻组织样本中3个基因（BRCA1、BRCA2和p53）的杂合性缺失以及2个基因（VEGF和Bcl-2）的表达情况。每个样本在取样和分析前均由病理学家进行评估。
对三种类型的组织进行了分子模式分析：健康乳腺组织（65个样本）、DCIS（25个样本）和浸润性乳腺癌（42个样本）。在22.3%的浸润性癌样本和13.4%的DCIS样本中检测到BRCA1杂合性缺失；在32.1%的浸润性癌样本和14.1%的DCIS样本中检测到BRCA2杂合性缺失；在35.6%的浸润性癌样本和33.2%的DCIS样本中检测到p53杂合性缺失。VEGF在15.3%的浸润性癌样本和8.3%的DCIS样本中过度表达。在13.2%的浸润性乳腺癌样本和7.1%的DCIS样本中检测到Bcl-2过度表达。
我们证实，相当一部分DCIS具有与浸润性癌相似的分子模式。这些分子变化可作为DCIS进展为浸润性癌的潜在标志物，或者可识别具有潜在浸润性的DCIS亚组。
